{"cluster": 63, "subcluster": 13, "abstract_summ": "The recent publication of Cao et al in the NEJM[1] showed that lopinavir/ritonavir treatment did not accelerate clinical improvement compared with standard of care.Developing new drugs from scratch is a lengthy process, thus impractical to face the immediate global challenge.While using such repurposed drugs individually may ultimately not yield a significant clinical benefit, carefully combined cocktails could be very effective, as was for HIV in the 1990s; the urgent question now being which combination.Since the beginning of the outbreak of severe acute respiratory syndrome (SARS) coronavirus (CoV) 2 lopinavir/ritonavir was selected for treatment.According the limited experimental evidences, it is hypothesized that sofosbuvir might be a potential option to improve care of patients with COVID-19 especially at the start of the disease and before invasion of the virus into the lung parenchymal cells.", "title_summ": "Drug repurposing strategies for COVID-19SARS-CoV-2 and HIV protease inhibitors: why lopinavir/ritonavir will not work for COVID-19 infection.Sofosbuvir as a potential option for the treatment of COVID-19.", "title_abstract_phrases": "The recent publication of Cao et al in the NEJM[1] showed that lopinavir/ritonavir treatment did not accelerate clinical improvement compared with standard of care.Developing new drugs from scratch is a lengthy process, thus impractical to face the immediate global challenge.While using such repurposed drugs individually may ultimately not yield a significant clinical benefit, carefully combined cocktails could be very effective, as was for HIV in the 1990s; the urgent question now being which combination.Drug repurposing strategies for COVID-19COVID-19 has now been declared a pandemic and new treatments are urgently needed as we enter a phase beyond containment.Since the beginning of the outbreak of severe acute respiratory syndrome (SARS) coronavirus (CoV) 2 lopinavir/ritonavir was selected for treatment."}